OrbusNeich Medical Group Announces First Patient Enrollment in Japanese Clinical Trial for Proprietary Drug-Coated Balloon
Key Highlights
- First patient enrolled in Japan pivotal clinical trial (OM-0031) for coronary paclitaxel drug-coated balloon (DCB).
- The trial is a major milestone for OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or “the Company”) in expanding its footprint in Japan’s interventional cardiology market.
- The DCB uses the Company’s proprietary drug-coating technology built on an established balloon platform, aiming for superior deliverability and precise drug transfer.
- Potential for regulatory approval and commercial launch in Japan, a significant market for interventional cardiology devices.
Detailed Report
OrbusNeich Medical Group Holdings Limited has announced a significant business update: the first patient has been enrolled in its pivotal Japanese clinical trial (OM-0031) to evaluate its proprietary coronary paclitaxel drug-coated balloon (DCB). This marks a critical step in the Company’s efforts to solidify its leadership in the high-growth Japanese market for interventional cardiology.
The innovative DCB is engineered to address complex clinical needs in the treatment of coronary artery disease. The device’s key features include:
- Outstanding deliverability, allowing interventionalists to navigate challenging and severely stenotic lesions with ease.
- Adoption of OrbusNeich’s proprietary drug-coating technology, enabling efficient and uniform paclitaxel transfer to the arterial wall.
- Precise therapeutic dosing and support for optimal vascular healing, while also maintaining robust trackability and crossability.
- Ability to deliver anti-proliferative therapy without leaving a permanent implant, addressing critical requirements in modern interventional cardiology.
About the Clinical Trial (OM-0031)
- The OM-0031 trial is a prospective, multi-center study targeting patients with coronary artery disease, especially those with de novo lesions in both small and large vessels, and patients with in-stent restenosis (ISR).
- The primary endpoint is target lesion failure (TLF) at six months’ follow-up.
- Enrollment will span 25 leading cardiovascular centers across Japan, with completion targeted by the end of 2027.
- The data from this trial will underpin OrbusNeich’s regulatory submission to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for marketing approval.
Potential Impact for Investors and Shareholders
- Market Opportunity: Successful commercialization of the DCB in Japan could unlock substantial new revenue streams and strengthen OrbusNeich’s market leadership in Asia.
- Growth Catalyst: A positive trial outcome and regulatory approval would likely be viewed favorably by the market, potentially driving share appreciation.
- Investment Risk: As the trial and regulatory processes are ongoing, there is inherent uncertainty. Investors should monitor updates closely.
- Shareholder Advisory: The company explicitly advises shareholders and potential investors to exercise caution when trading OrbusNeich shares until further updates are provided, signaling that this development is material and could influence share price.
Corporate Update
The announcement was made by Mr. David Chien, Chairman, Executive Director, and Chief Executive Officer of OrbusNeich Medical Group Holdings Limited, on July 22, 2026.
The Board comprises Mr. David Chien, Ms. Kwai Ching Denise Lau, and Mr. Wing Shing Chen as Executive Directors; Mr. Ting San Peter Lionel Leung as Non-executive Director; and Mr. Yip Keung Chan, Mr. Ka Keung Lau (BBS, MH, JP), and Dr. Lai Fan Gloria Tam as Independent Non-executive Directors.
Conclusion
This announcement marks a major strategic milestone for OrbusNeich as it pushes forward in the competitive Japanese market. The success of the OM-0031 trial could be a significant value driver for the Company and its shareholders.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with professional advisers before making investment decisions. Shareholders are advised to exercise caution when trading shares of OrbusNeich as clinical and regulatory outcomes remain uncertain.
奧博斯醫療集團宣布日本臨床試驗首位患者入組 — 新一代藥物塗層球囊
重點摘要
- 首位患者已成功入組日本關鍵性臨床試驗（OM-0031），評估冠狀動脈紫杉醇塗層球囊（DCB）。
- 此舉是奧博斯醫療集團控股有限公司（「奧博斯」或「本公司」）拓展日本介入心臟病市場的重要里程碑。
- DCB採用本公司自主研發的塗藥技術及成熟球囊平台，致力於提升可送達性及精準藥物釋放。
- 有望獲得日本監管批准並於日本市場上市，為公司開創新增長點。
詳細報導
奧博斯醫療集團控股有限公司公佈，其自主研發的冠狀動脈紫杉醇塗層球囊（DCB）於日本關鍵性臨床試驗（OM-0031）中，首位患者成功完成入組。這是公司鞏固其在日本高增長介入心臟病市場領導地位的重要一步。
該創新型DCB產品專為解決冠狀動脈疾病的複雜臨床需求而設計，具備以下特點：
- 優異的可送達性，便於介入醫生處理複雜及嚴重狹窄病變。
- 採用自主研發的塗藥技術，高效且均勻地將紫杉醇傳遞至動脈壁。
- 確保精確治療劑量及有利於血管癒合，同時保持良好可追蹤性與可穿透性。
- 可無植入物情況下，非侵入式輸送抗增殖藥物，滿足現代介入治療關鍵需求。
關於OM-0031臨床試驗
- OM-0031是一項前瞻性、多中心臨床研究，招募冠狀動脈疾病患者，尤其針對大小血管新發病變及支架內再狹窄（ISR）患者。
- 主要終點為六個月隨訪時的目標病變失敗率（TLF）。
- 預計將於全日本25家領先心血管中心持續招募，並於2027年底前完成入組。
- 臨床數據將用於向日本醫藥品醫療機器綜合機構（PMDA）申請上市批准。
投資者及股東需知
- 市場前景：若在日本成功商業化，將大幅擴展收入來源，鞏固亞洲市場領先地位。
- 增長催化劑：臨床試驗及監管審批若進展順利，或將推動公司股價上升。
- 風險提示：臨床及審批過程中仍有不確定性，投資者應持續關注最新進展。
- 股東建議：公司明確建議投資者於進一步公告前審慎買賣股份，反映此消息屬重大事項或會影響股價。
公司動態
公告由董事會主席、執行董事兼行政總裁錢大衛先生於2026年7月22日發出。
董事會成員包括：錢大衛先生、劉桂貞女士、陳永成先生（執行董事）；梁廷山先生（非執行董事）；陳業強先生、劉家強先生（BBS, MH, JP）、譚麗芬醫生（獨立非執行董事）。
總結
本次公告標誌著奧博斯在日本市場的重大戰略進展。OM-0031試驗的成功將成為公司及股東的重要價值驅動因素。
免責聲明：本文僅供參考，並不構成任何投資建議。投資者需自行研究及諮詢專業顧問。臨床及監管結果尚未確定，買賣股份應審慎。
